The drugmaker, which develops cancer treatments, earns about a third of its drug revenue from the U.S., representing its biggest market outside of Japan, according to the report.
“Takeda has for many years been reasonable in its price increases in the U.S. and we are very committed to single-digit price increase,” Takeda CEO Christophe Weber told reporters Wednesday.
The company acquired Ariad Pharmaceuticals for $5.2 billion in January and said it was looking for more acquisitions to expand its drug portfolio and move to more overseas markets, according to the report.
More articles on suply chain:
Shifting drug production back to US could raise prices: 5 takeaways
Mayo Clinic physician: A stripped down FDA would be ‘chaotic’
Bard Peripheral Vascular recalls Halo One guiding sheath
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
